Skip to main content

SLAS Europe 2023 Main banner

Tweets by SLAS Europe 2023

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Presentation Icons

Short Course

On Demand

Shaping the Future of Therapeutics

Shaping the Future of Therapeutics

Type here to filter the list

(1002-A) A multidisciplinary approach for the identification of Tsg101 UEV ligands with potential as novel broad spectrum antivirals

Favorite
(1008-A) High-content antiviral screening assay for enteric viruses using human intestinal organoids

Favorite
(1013-B) Identification of an Effective Ribonucleoside Analogue and Immunomodulatory Imide Drug (IMiD) Combination for Multiple Myeloma

Favorite
(1014-A) Modeling heat generation in closed liquid handling systems

Favorite
(1020-A) A modular robotic platform for the discovery and development of antibiotics

Favorite
(1025-B) High-throughput screening of small molecules targeting FoxP3 in regulatory T cells for cancer treatment

Favorite
(1031-B) A combined TDP43-Tau cellular model for the understanding of LATE-NC Proteinopathy

Favorite
(1032-A) Development of novel thiosemicarbazones as multi-target directed ligands for the treatment of Alzheimer’s disease

Favorite
(1036-A) Overcoming Drug Resistance in Breast Cancer using High Throughput Combination Screenings

Favorite
(1043-B) Uniform and Mass Production of Three-dimensional Cell Spheroids Using Precise Bioink Dispensing Technology

Favorite
(1048-A) Affinity selection-mass spectrometry towards membrane protein drug discovery

Favorite
(1052-A) Antagonists of Transient Receptor Potential-Mucolipin 1 as new therapeutic opportunities for cancer

Favorite
(1059-B) Automation of organoid assays for drug screening

Favorite
(1069-B) Enhancing Functional Precision Medicine by Utilizing Ex Vivo Drug Sensitivity Testing of Primary Patient Cells

Favorite
(1070-A) Evaluation of the bioactivity of compounds using Cell Painting assay and alternative High-Content assays

Favorite
(1080-A) Investigating the in vitro enhancement of differential immune cell responses by immunotherapies pembrolizumab, blinatumomab and trastuzumab

Favorite
(1081-B) Kinetic evaluation of slow onset hERG blockers through development of an enhanced automated electrophysiology assay panel

Favorite
(1083-B) KRAS PROTAC-mediated degradation and its implication in MAPK pathway activation: SureFire Ultra as a unique technology for measuring downstream effects.

Favorite
(1086-A) Multivariate analysis platform for early detection and severity evaluation of biofilm-associated infections (BAI)

Favorite
(1091-B) PT-OPENSCREEN: The Portuguese Infrastructure for Chemical Biology and Genetics

Favorite
(1100-A) The impact of ruxolitinib and tocilizumab on IL-6 evoked phospho-STAT3 induction across immune cell subsets

Favorite
(1101-B) The use of SureFire Ultra assays to demonstrate PROTAC mediated degradation and the effects on signalling pathways.

Favorite